Grail multicancer detection test wins FDA advisers’ backing

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 24 Sept, 15:11 UTC

Members of the molecular and clinical genetics panel said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings.

science

Sources

• T2Grail multicancer detection test wins FDA advisers’ backingBioPharma Dive / Healthcare Dive / MedTech Dive24 Sept, 15:11